We are pleased to announce that our laboratory has successfully passed the certification process and has met all the requirements of the international standard EN ISO 13485:2016.
We have received an accreditation certificate in accordance with ČSN EN ISO 15189 ed. 3:2023
Based on meeting the requirements for quality and competence of a medical laboratory, the Lipidica laboratory received a Certificate of Accreditation according to ČSN EN ISO 15189 ed. 3:2023.
This milestone is essential for us to continue with our clinical study, bringing us closer to our goal of enabling the early detection of pancreatic cancer in clinical practice with potential to save many lives each year.
Lipidica has a US patent!
Method for detecting pancreatic cancer
We are happy to share with you great news – our innovative method for early detection of pancreatic cancer was successfully patented in the United States of America in March! This significant milestone is the result of an almost five-year process, during which it underwent a thorough assessment by the US patent offices.
The patent applies to our diagnostic method, which enables the detection of pancreatic cancer using the analysis of lipids from blood. A detailed description of the method on 75 pages confirms its scientific and clinical value.
Obtaining a US patent significantly advances the potential of using screening tests and complements patents granted in the EU, Japan and Singapore.
Publication of an article in the Czech Society of Clinical Biochemistry journal
Clinical Biochemistry and Metabolism 3/2024
The Lipidica research team published an article in the Czech Society of Clinical Biochemistry journal Clinical Biochemistry and Metabolism.
World Pancreatic Cancer Day
21. 11. 2024
Today we commemorate World Pancreatic Cancer Day, one of the most insidious types of cancer with a low chance of cure if not detected early. This disease often occurs without significant symptoms until advanced stages, which significantly reduces the possibilities of treatment and worsens the prognosis of patients.
We attended the IMSC 2024 conference
The International Mass Spectrometry Conference (IMSC)
The International Mass Spectrometry Conference (IMSC) is a world-renowned conference where news and modern trends in the field of mass spectrometry are presented. This conference is held regularly every 2 years and the 25th edition took place in the second half of August in Melbourne, Australia.
Approval of a clinical study for the early detection of pancreatic cancer
The State Institute for Drug Control (SÚKL) approved the clinical performance study of in vitro diagnostic device Lipidica
At the end of July, a study entitled “Clinical performance of medical device software Lipidica for processing data generated by lipidomic analysis in pancreatic cancer screening” was approved (protocol number: Lipidica_01-2024, version 1.0). The study is registered in the database ClinicalTrials.gov.
Lipidica builds on the results of ground-breaking research from the ERC CZ grant
ERC Scientific Mini-conference 13.6.2024, CEITEC, Brno
Co-founder of the spin-off company Lipidica, a.s. and currently ERC Advanced grant holder, prof. Michal Holčapek from the University of Pardubice presented his project focused on new dysregulations of lipids and the complexity of the mechanism of metabolic changes that cause these dysregulations. The conference was held with the participation of the president of the European Research Council (ERC), Maria Leptin and 12 holders of prestigious ERC grants from the Czech Republic.
We participated in an international comparison of laboratories
International Lipidomics Society
At the beginning of 2024, we joined a project organized by the International Lipidomic Society, which aims to harmonize concentrations for selected lipids in human plasma. This study should help to define the correct procedures in quantitative lipidomic analysis and at the same time reveal pitfalls and shortcomings of individual methods.
